Oncology · Medical Literature
[News] Research in Brief
Abstract
Daraxonrasib—an oral RAS(ON) multiselective inhibitor—significantly improves survival compared with standard chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma, according to the phase 3 RASolute 302 trial. Eileen M O’Reilly and colleagues randomly assigned patients to receive either daraxonrasib (n=248) or investigator's choice of chemotherapy (n=252). Overall, 91·8% of patients had RAS G12 mutations.
Clinical relevance
In patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC), does the oral RAS(ON) multiselective inhibitor daraxonrasib improve overall survival and progression-free survival compared with investigator's choice of standard cytotoxic chemotherapy? __SNAPSHOT__ {"studyDesign":"Phase 3, international, open-label, randomized controlled trial (first interim analysis reported); NCT06625320","setting":"Global, multicenter; sites across North America, Europe, and Asia","sampleSize":"n=500 (daraxonrasib: n=248; chemotherapy: n=252)","population":"Adult patients with histologically or cytologically confirmed previously treated mPDAC; ECOG performance status 0–1; measurable disease per RECIST v1.1; adequate organ function; 91.8% harbored RAS G12 mutations; also included patients with RAS G13, Q61 mutations, and RAS wild-type tumors; all had received one prior line of chemotherapy for metastatic disease; median age 66 years, approximately half male","intervention":"Daraxonrasib 300 mg orally once daily — a noncovalent, multiselective RAS(ON) tri-complex inhibitor targeting the active GTP-bound state of both mutant and wild-type RAS isoforms","comparator":"Investigator's choice of standard-of-care cytotoxic chemotherapy (intravenous)","primaryOutcome":"Dual primary endpoints: (1) overall survival (OS) and (2) progression-free survival (PFS) by Blinded Independent Central Review, both assessed in the RAS G12 mutation subpopulation","followUp":"Not reported (trial described as ongoing at time of this interim analysis)","fundingSource":"Industry (Revolution Medicines)"}
Key findings
In the RAS G12 population (primary endpoint population): median OS was 13.2 months with daraxonrasib vs. 6.6 months with chemotherapy (HR 0.40, P<0.001); median PFS was 7.3 months vs. 3.5 months (HR 0.45, P<0.001). In the overall intent-to-treat (ITT) population (key secondary endpoints): median OS was 13.2 months vs. 6.7 months (HR 0.40, P<0.001); median PFS was 7.2 months vs. 3.6 months (HR 0.49, P<0.001). The absolute OS gain was approximately 6.5–6.6 months across both populations (calculated). The HR of 0.40 corresponds to a 60% relative reduction in the risk of death. NNT cannot be calculated from survival data without individual patient-level time points. Regarding safety: treatment-emergent adverse events (TEAEs) were reported in 100% of the daraxonrasib group and 97.7% of the chemotherapy group; grade ≥3 adverse events occurred in 61.8% vs. 69.6%, respectively, suggesting a numerically more favorable high-grade toxicity burden with daraxonrasib, though no formal statistical comparison of safety rates was reported in the available abstract. No new safety signals were identified.
Practice implications
This trial establishes daraxonrasib as superior to standard second-line chemotherapy in previously treated mPDAC across both the RAS G12 subpopulation and the broader ITT population. The magnitude of OS benefit — approximately doubling median survival with an HR of 0.40 — is both statistically significant and highly clinically meaningful in a disease where second-line options have historically offered minimal survival gain. The oral once-daily formulation and numerically lower rate of grade ≥3 adverse events relative to IV chemotherapy further enhance clinical appeal. Importantly, benefit was observed regardless of RAS mutation status (including RAS wild-type tumors), broadening the potentially eligible population beyond mutation-selected cohorts. However, several caveats apply: (1) the full peer-reviewed publication was simultaneously released in NEJM (May 31, 2026), but the Lancet GH source document referenced here is a brief news summary — detailed subgroup analyses, quality-of-life data, objective response rates, and duration of response results are not fully characterized in the abstract; (2) data derive from a first interim analysis of an ongoing trial — mature OS data are not yet available; (3) the trial is industry-funded, which warrants standard scrutiny; (4) the open-label design introduces potential ascertainment bias for patient-reported outcomes, though OS is an objective endpoint not susceptible to this; (5) generalizability to patients with ECOG PS ≥2, those with prior KRAS-targeted therapy, or those beyond second-line is not established. __LIMITATIONS__ 1. Industry funding (Revolution Medicines) with potential for optimistic framing of interim results. 2. Open-label design: introduces bias for subjective endpoints (e.g., QoL), though OS is robust. 3. First interim analysis only — trial is ongoing; mature OS curves and long-term safety data are not yet available. 4. Detailed subgroup analyses (by RAS variant type, prior regimen, geographic region, performance status) are not reported in the available summary. 5. Objective response rate, duration of response, and patient-reported QoL results referenced but not quantified in the available abstract. 6. The comparator 'investigator's choice of chemotherapy' introduces heterogeneity in the control arm that may inflate apparent treatment effect depending on regimen selection. 7. Patients requiring ECOG PS 0–1 limits applicability to patients with poorer functional status — a common real-world scenario in relapsed mPDAC. 8. Whether prior or concurrent KRAS-targeted therapy (e.g., sotorasib, adagrasib) affects daraxonrasib efficacy is not addressed. __BOTTOM_LINE_CATEGORY__ practice_changing __BOTTOM_LINE__ In previously treated mPDAC, daraxonrasib 300 mg once daily nearly doubled median OS compared with standard chemotherapy (13.2 vs. 6.6–6.7 months; HR 0.40, P<0.001) with a numerically lower rate of grade ≥3 adverse events, representing the most substantial survival benefit demonstrated in this setting to date. The FDA has granted Breakthrough Therapy Designation and an expanded access program is active, with regulatory submissions underway. Clinicians treating second-line mPDAC should anticipate daraxonrasib as an imminent new standard of care pending regulatory approval, applicable across the full spectrum of RAS mutation subtypes and potentially RAS wild-type disease.